
Funds Received from Participating Corporations for Fiscal Year 2023



In fiscal year 2023, ACNP had a total of \$10,921,010 in revenue from the following sources:

All funds from pharmaceutical companies are listed below.

Participating Corporations Fees

Abbvie	\$25,000
Acadia Pharmaceuticals	\$25,000
Alkermes, Inc.	\$50,000
Axsome	\$12,500
Boehringer Ingelheim	\$50,000
Cen Exel	\$25,000
Cerevel Therapeutics, LLC	\$50,000
Clinilabs	\$6,000
COMPASS Pathways	\$12,500
Delix Therapeutics	\$12,500
Eisai Inc.	\$12,500
Engrail	\$6,000
H. Lundbeck	\$50,000
Intra-Cellular Therapies, Inc.	\$12,500
IQVIA	\$6,000
Janssen	\$25,000
Karuna Therapeutics	\$50,000
Merck	\$25,000
Neumora	\$25,000
Neurocrine Biosciences, Inc.	\$25,000
Otsuka Pharmaceutical Development, Inc.	\$75,000
Roche	\$25,000
Sage Therapeutics, Inc.	\$75,000
Signant Health (Bracket Global)	\$12,500
Sunovion Pharmaceuticals, Inc.	\$50,000
Supernus Pharmaceuticals	\$25,000

Educational Grants

Company	Program Supported	Amount
Sunovion	Annual Meeting	\$ 10,000.00